信立泰(002294.SZ):YOLT-101获临床试验默示许可

智通财经
Jul 14, 2025

智通财经APP讯,信立泰(002294.SZ)公告,公司引进的创新基因编辑药物YOLT-101注射液已获得国家药品监督管理局的临床试验默示许可,该药片适应症为杂合子型家族性高胆固醇血症(HeFH)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10